This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer)
Signed informed consent that will be put on file
No informed consent obtained
Specimen unacceptable/degraded/etc.
Individuals who are not yet adults (infants, children, teenagers)
Pregnant women
Patients diagnosed with bladder cancer, lung cancer, gastric/stomach cancer, or liver cancer seen in routine clinic appointments within the University of California (UC) Davis Health System and contributing University of California Minority PDX (UCaMP) institutions
Case-only
Cross-sectional
Biospecimen Collection
Procedure/SurgeryUndergo collection of tumor tissue, blood, saliva, and urine samples
Establish and characterize at least 200 patient-derived cancer xenografts (PDXs)
The investigators will establish and characterize at least 200 PDXs, and utilize these PDXs in preclinicial testing of single agents and drug combinations that help guide future clinical decision-making emphasizing the largest racial/ethnic minority populations residing in California: Hispanic/Latino Americans (\[HLAs), Asian Americans/Native Hawaiians/Pacific Islanders (AANHIPIs), and African Americans (AAs) compared to Non-Hispanic Whites (NHWs).
Click on the lead sponsor to view all of their trials.
University of California, Davis
Lead sponsor
National Cancer Institute (NCI)
Collaborator
